


Chairman Torbjørn Bjerke

Corporate update

Next stage of value creation in SynAct Pharma: Mission

**Further Establish SynAct Pharma as The Leading Biotech Company
within the Field of Inflammation Resolution**

Why initial focus on Rheumatoid Arthritis?



Resomelagon could be well suited to address the unmet needs in RA

Important Milestones in 2022

- ✓ 1H22 – Listed on Nasdaq Stockholm Main Market
- ✓ 2H22 – Filed and opened US IND
- ✓ 2H22 – Initiated Phase 2b (P2b) in early severe RA
- ✓ 2H22 – Initiated Phase 2a/b in DMARD-IR RA under FDA IND
- ✓ 1H23 – Completed acquisition of TXP Pharma

SynAct acquired TXP Pharma adding a portfolio of complimentary peptide-based melanocortin assets

Resomelagon (AP1189)

- Being developed as an
Once daily oral therapy for:
- Early severe RA (P2b)
 - DMARD-IR RA (P2a/b)
 - Membranous nephropathy (P2a)
 - Virus induced respiratory insufficiency

TXP Peptides

- Being developed for:
- **TXP-11:** Intravenous administration for organ protection in major surgery
 - Other pre-clinical peptides for inflammatory and orphan diseases

Important Milestones in 2023

1. **EXPAND** P2b 12 weeks in severe treatment naïve RA patients in combination with methotrexate (MTX)
2. **RESOLVE** Phase 2a (P2a) 4 weeks in RA patients experiencing an incomplete response to MTX (P2b protocol filed)
3. P2a 12 weeks in patients with nephrotic syndrome (iMN) experiencing severe proteinuria
4. Develop pre-clinical pipeline into clinical ready opportunities

SynAct Pharma – Pipeline overview

Asset	Indication	Pre-clinical	Phase I	Phase IIa	Phase IIb	Phase III
AP1189	Rheumatoid Arthritis Severe treatment-naïve with MTX	Completed			Ongoing	Resolve Part B (Approved in IND)
	Rheumatoid Arthritis DMARD-IR	Completed		Ongoing	Resolve Part B (Approved in IND)	
	Nephrotic syndrome (iMN)	Completed		Ongoing		
	Virus- Induced Respiratory Insufficiency	Completed				
TXP-11	Prevention of organ failures in complicated surgery	Ongoing				
Small Molecules and Peptides	Autoimmune and inflammatory conditions	Ongoing				



Completed



Ongoing



Resolve Part B
(Approved in IND)

Recent Value Creating Deals within the Field of Inflammatory Diseases



Prometheus
Biosciences



- Acquisition total deal value US\$ 11 billion
- Merck is picking up a experimental treatment for ulcerative colitis and Crohn's disease and building up its presence in immunology
- Prometheus is in clinical phase II within Ulcerative Colitis and Morbus Crohn (IBD)

- Acquisition total deal value US\$ 6.7 billion
- Pfizer gaining potential therapies targeting immuno-inflammatory diseases in phase II
- Focus will be on (IBD) Inflammatory Bowel Disease